14102 studies
OBJECTIVE: To address previous inconsistencies in reports of differential adherence to diabetes medications, we examined medication adherence and evaluated treatment group differences in a substudy of participants in the Glycemia Reduction Approaches…
The comparative effects of pharmacological treatment, bariatric surgery, and diet on insulin resistance (IR) remain unclear.To study the comparative effects of the methods on IR: pharmacologic, bariatric surgery, and very-low-calorie diet (VLCD) in p…
The prevalence of obesity continues to rise, with notable increase in stage III obesity in North America. The accumulation of excess adipose tissue can impair health with cardiovascular disease being the leading cause for increased mortality in peopl…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in patients with chronic kidney disease (CKD), but existing evidence regarding their efficacy and safety remains inconsistent. To evaluate the cardiorenal outcomes and adverse effe…
OBJECTIVE: Arteriovenous fistulae (AVF) are necessary for hemodialysis in patients with end-stage kidney disease (ESKD), but are frequently complicated by thrombosis, stenosis, and need for revision. Glucagon-like peptide-1 receptor agonists (GLP-1RA…
BACKGROUND: Statin product labels (eg, Summaries of Product Characteristics [SmPCs]) list certain adverse outcomes as potential treatment-related effects based mainly on non-randomised and non-blinded studies, which might be subject to bias. We aimed…
BACKGROUND: Physical activity helps maintain a healthy stable body weight. One mechanism underlying this beneficial effect could be the improved coupling between energy intake and expenditure, since hunger and satiety are better regulated in active i…
Recent revisions of Alzheimer’s Disease (AD) definitions by two leading research groups—the Alzheimer’s Association and the International Working Group—reflect divergent approaches: the former promotes a strictly biological definition, while the latt…
Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research. Mo…
The intricate interplay of physiological, psychological, and social factors presents considerable challenges in addressing heart failure. It is imperative to comprehend the epidemiology and pathophysiology, identify predictors and their influence on…
BACKGROUND: Obesity is a chronic, multifactorial disease associated with significant metabolic, physical, and psychosocial complications. Although advances in pharmacologic therapy-particularly glucagon-like peptide-1 (GLP-1)-based agents-have expand…
Limited available data indicate that glucagon-like peptide-1 (GLP-1) medications may significantly reduce weight and binge-eating symptoms among patients with binge-eating disorder. However, experts express concern about the potential for GLP-1 medic…
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease closely associated with obesity and metabolic dysfunction, which contribute to increased disease severity, reduced treatment response, and impaired quality of life. Incretin-based t…
AIM: This study aims to examine weight-loss history and pre-treatment concerns, and their associations with current functioning and well-being in adults undergoing incretin-based pharmacotherapy for obesity. MATERIALS AND METHODS: This cross-sectiona…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become an important therapeutic option for metabolic disorders. Their development, from the early identification of exendin-4 in Gila-monster venom to the creation of long-acting analogues and…
Lecanemab, the first anti-amyloid therapy approved by the European Medicines Agency, has demonstrated a statistically and clinically significant but moderate slowing of decline in early Alzheimer's disease (AD). In contrast, its long-term impact on t…
Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), represents a rapidly expanding global health challenge with substantial public health and economic consequences. Recent advances in antidiabetic therapy-including dipeptidyl peptidase-4…
UNLABELLED: Diabetes is a growing global health concern, affecting 537 million adults worldwide, significantly contributing to mortality and disability. Cluster analysis, a branch of Unsupervised machine learning (ML), has been increasingly used to i…
The introduction of incretin-based therapy has brought a significant transformation in the treatment of type 2 diabetes and obesity. It works by augmenting natural incretin hormones to enhance insulin secretion and suppress glucagon release in a gluc…
INTRODUCTION: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used for weight management and type 2 diabetes, but reports of reduced skin laxity and volume have raised aesthetic concerns. This study evaluates the first integrated ski…